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INTRODUCTION 
Since the diagnosis of HIV/AIDS in the 1980s, a number 
of recommendations, guidelines have been constituted to 
mitigate the magnitude of HIV. As a result, interventions 
have ranged from: - providing palliative care to HIV 
infected patients; extending HIV treatment to HIV 
patients with opportunistic infections, patients in WHO 
stage III and IV, patients with CD4 T cell count less than 
500 and currently HIV viral load less than 200 
copies/ml.
1
 With current studies indicating that viral load 
suppression increases survival among HIV patients and 
having in mind a series of HIV interventions not 
effectively working, there is need to explore the efficacy 
of viral load suppression to HIV patients with varying 
characteristics and exposure factors.
2-5
  
For instance, the responsiveness to treatment among HIV 
patients in rural and urban communities, poor and 
wealthy households, under developed and developed 
societies, old and young, different races, sexual 
orientation among others varies across the board.
7
 
Viral load (VL) refers to the amount of HIV in a blood 
sample reported as the number of HIV RNA copies in a 
millilitre of blood. Uptake of antiretroviral drugs helps in 
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the treatment and prevention of HIV infections. The drugs 
fight virus through interfering or stopping reproduction of 
HIV in the body system, thus reducing the amount of the 
virus in the body. The overall aim of antiretroviral 
therapy (ART) is to suppress the HIV patient’s VL to 
undetectable level, to the extent of the virus not being 
detected through a VL test. The VL test entails drawing 
dried blood samples being used in identifying HIV VL 
with treatment failure limit of 1000 copies/ml. On the 
other hand, virological failure happens when VL is more 
than 1000 copies/ml on two consecutive episodes of VL 
tests every three months with adherence support and six 
months after initiating on a new ART regimen. Currently, 
WHO recommends VL tests to be done at six months 
from the time of enrolling on ART and 12 months 
thereafter. An HIV patient is considered stable on ART 
when the following criteria is met: - active on ART drugs 
for a minimum of a year; not facing illnesses; has good 
understanding of lifelong adherence coupled with 
evidenced treatment success, implying two consecutive 
viral load tests reported below 1,000 copies/ml.
8
 
A study by Ford et al, revealed that AIDS-related 
illnesses and bacterial infections were the leading causes 
of hospital admission and mortality among adults.
9
 The 
causes among adults included malnutrition, wasting, 
parasitic infections, haematological disorders in the 
Africa while respiratory disease, psychiatric disorders, 
renal disorders, cardiovascular disorders, and liver 
disease in Europe. Haematological disorders were 
reported in North America and respiratory, neurological, 
digestive and liver-related conditions, viral infections, 
and drug toxicity in South and Central America. 
Tuberculosis (TB) is reported as the major cause of death 
among HIV patients in Africa, with mortality being high 
among adults compared to children. Much as free ART is 
accessible to most patients, HIV continues to contribute 
most of the reported deaths. To reverse this trend, there is 
need to prevent, treat and manage HIV by; use of 
condoms during sex, early testing, adhering to ART, 
being faithful to a sexual partner, embracing voluntary 
medical male circumcision (VMMC) as a prevention 
measure for negative males among others. It should be 
noted that people living with HIV often need counselling 
and psychosocial support, access to good nutrition, safe 
water and basic hygiene and managing opportunistic 
infections to maintain a high and long quality life.
8
  
To this effect therefore, the authors attempt to 
substantiate the evidence that viral load suppression 
entirely determines survival of HIV Patients on ART. 
METHODS 
Utilizing a comprehensive search approach by merging 
terms for survival of HIV patients and unsuppressed viral 
load, other opportunistic infections, age, non-
communicable diseases, poverty, geographical location, 
the authors searched NCBI and MEDLINE through 
PubMed, PMC, Embase, Google scholar to identify 
studies reporting VL and survival of HIV patients    
(Table 1).  
The authors focused on articles published from 2013 
when VL testing was intensified. Key consideration was 
given to articles written and/ or translated in English, 
publications focusing on HIV/AIDS, Viral Load, HIV 
publications from across the globe, and publications from 
authentic sources. The key words used included: - HIV, 
patients, ART, death, survival, poverty, unsuppressed, 
HIV, AIDS, death, tuberculosis, patient, NCD, OIs, viral 
load. Articles excluded by the authors included 
publications before 2013, publications not written and/ or 
not translated in English, articles not focused on HIV and 
AIDS, Articles from uncertified sources and articles 
without author details.  
The authors included a total of 15 articles. To obtain the 
final article number, the author framed the research 
question, defined key words and search terminologies. 
Thereafter, the author browsed into NCBI and 
MEDLINE, selecting the databases (PubMed, PMC, 
Embase, Google scholar), one at a time, inputting the 
search terms at different intervals, filtered by date of 
publication, free full article, human’s category and then 
selecting the article of preference. 
RESULTS 
Unsuppressed viral load  
Several studies reveal that risk of death among HIV 
patients is highly associated with viral load.
3-5,7 
This 
implies that the longer an HIV patient is on ART and 
adhering to treatment, the more likely the chances of viral 
suppression thus low risk of death. According to a series 
of studies, ART start date, social economic factors, 
stigma were contributing factors to death among HIV 
patients.
2-6
 However other studies reveal that the sex of an 
HIV patient did not affect viral load suppression, thus not 
associated with risk of death. The losses to follow up 
among HIV patients on ART triggered likelihood of 
death, given that most of the lost to follow up patients 
either dropped off treatment, did not adhere to treatment 
as prescribed by health care workers, leading to 
unsuppressed VL.
6 
Across the globe, for HIV patients to 
manage HIV associated symptoms and opportunistic 
infections (OIs), they apply a series of interventions 
including therapeutic, physical activity, psychological 
well-being like herbal medicines, faith healing, self-
prescription of medicines. As a result, most patients 
abscond from taking ART thus compromising VL 
suppression coupled with treatment failure, toxicities 
resulting from unproven herbal medicines.
10
 
It is important to note that VL does not entirely determine 
death among HIV patients but is a clinically ultimate 
cause of death among HIV patients. Some studies suggest 
that mortality among HIV positives is highly associated 
with several other causes including Tuberculosis, suicide, 
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geographical location, age, CD4 cell count, mode of 
transmission of HIV, drug failure, geographical location 
and HIV/TB co-management.
3-5,7,11
 For instance, in 
Uganda, most key populations including commercial sex 
workers, men having sex with men, injecting drug users, 
lesbians, transgender are criminalized populations and 
thus not likely to freely access HIV and viral load 
services as recommended. As a result, their adherence 
levels are compromised, registering unsuppressed viral 
load, multiple drug treatment failures among others.
4
 
Other categories of populations like fisher folks, the 
incarcerated and people in enclosed settings like soldiers, 
prison officers, adolescent girls and young women tend to 
have poor adherence to treatment, poor health seeking 
behaviour, thus compromising their health. It should be 
noted that men, across the board have a poor health 
seeking behaviour, no wonder their survival chances are 
slim compared to women on ART.
5
 
Table 1: Search approach. 
Natural language Term mapped to database vocabulary  
P (Patient) = Virally suppressing 
patient 
HIV viral load (PubMed, PMC, Embase, Google scholar) 
I (Indicator) = Viral load Suppression Viral load suppression (PubMed, PMC, Embase, Google scholar) 
C (Comparison) = HIV patient    
VL, OIs, Age, NCDs, Poverty, Residence (PubMed, PMC, Embase, Google 
scholar) 
O (Expected outcome) = survival  Dead, Alive (PubMed, PMC, Embase, Google scholar) 
 
Opportunistic infections  
Opportunistic diseases among HIV patients are a result of 
either lack of immune defences or availability of 
environmental microbes and pathogens. The common 
OIs/diseases are: - bacterial (TB, MAC, pneumonia, 
septicaemia; protozoal (PCP, microsporidiosis, 
toxoplasmosis, leishmaniasis, isosporiasis, 
cryptosporidiosis); fungal (candidiasis, cryptococcal 
meningitis, penicilliosis); viral (cytomegalovirus, herpes 
zoster); Kaposi sarcoma, squamous cell carcinoma and 
lymphoma. These OIs continue to cause mortality among 
HIV patients despite improvements in ART access and 
management due to poor adherence, treatment failure, 
unknown HIV status. Amidst the presence of combination 
prevention and treatment services, HIV patients still 
manifest severe OIs despite a virological and 
immunological reaction to ART. The late delayed 
identification of and management of immune 
reconstitution inflammatory syndrome has highly resulted 
into death.
8
 
Non-communicable diseases 
Non communicable diseases, comprising four types 
(cancer, chronic respiratory diseases, cardiovascular 
diseases and diabetes) is the leading cause of death 
globally, largely among older people and HIV patients. 
The rates are on the increase in developing countries, 
majorly due to smoking habits, alcohol abuse, less 
physical activity, poor diet and partly because HIV 
management continues to focus on managing acute not 
chronic diseases. Studies have revealed that HIV patients 
have a higher risk of cardiovascular disease, cancer, 
obesity, chronic obstructive pulmonary disease with a 
steady increase in cases among women, older adults and 
those with lower education. NCDs were further 
associated with low CD4 thus persistent inflammation of 
immune system.
12
 
Age and sex 
According to Agolory et al, about 50% men and women 
do not know their HIV status.
13
 HIV incidence reported 
higher among females than males and adolescents have 
the lowest HIV testing rates. Among the contributing 
factors for adolescents are inadequate information about 
access to HIV treatment and prevention, lack of HTS 
services and settings friendly to adolescents. Among men, 
stigma, health seeking behaviour, barriers related to 
socio-economic and health facility dynamics affect their 
urge to test. Additionally, VL uptake is also low among 
paediatric and adolescents, partly due poor drug 
adherence, inadequate ARV formulations that are 
paediatric friendly, nondisclosure, limited peer support 
network, stigma, non-compliance to existing guidelines 
among others. 
Other studies consider particular age categories of much 
priority over others in mitigating death among HIV 
patients. According Arpadi et al, HIV positive children 
and infants have a poor viral load suppression compared 
with HIV positive adults on ART, thus children and 
infants are more likely to die than the latter. The 
limitations faced by children and infants as reported by 
Arpadi et al range from poor health care system, limited 
allocation of resources to infant and children HIV care 
including wanton viral load monitoring. Much as life 
expectancy of adult HIV patients has continued to drop, 
women have registered more gains than men. This 
disparity is attributed to: - the difference of HIV mortality 
across specific age groups; women are more likely to 
recover from HIV coinfections compared to men; women 
enrolling for ART more than men. 
Geographical location and poverty  
Patients in hard to reach locations have a high likelihood 
of dying compared to patients closer to health facilities 
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providing ART services. Since the discovery of HIV in 
the 1980s, the different strategies presented to curb the 
HIV epidemic have increasingly registered progress. 
Until the 1990s, HIV patients were majorly provided 
palliative care until their death. ARVs at the time were 
very expensive and a preserve of the rich and well 
positioned in society. Later on, HIV testing was extended 
to most populations and ARVs provided to the very sick 
at a free cost. Increasingly, with the increase in funding 
from the United States Government under the PEPFAR 
Program, more people continued to access treatment for 
HIV at zero cost and many more got to test and know 
their HIV status. This eventually spurred access to HIV 
care as most health systems were strengthened by 
accrediting more health facilities to provide HIV, health 
workers trained on management of HIV using WHO 
staging guidelines, use of CD4 machines for testing and 
eventually viral load screening.
8
 Using the UNAIDS 90 
90 90 approach, more people know their HIV status, the 
HIV positive are increasingly starting ART, staying on 
ART, adhering to ART, taking viral load tests and 
clinically improving. This is resulting from the gains 
registered and confidence built by different stakeholders 
with commitment to accelerate HIV epidemic control.
14
  
According to Coninck et al, patients recently started on 
ART in the western world registered lower risk of dying, 
due to improved health system coupled with good 
adherence to treatment, timely management of OIs and 
co-infections, limited access to toxic drugs.
7
 Despite this 
improvement however, these patients are more at risk of 
dying compared to non-HIV patients.
7
 In developing 
countries like the Sub Saharan Africa (SSA), there is 
relative efforts needed to bridge the unmet need for ART 
using different scale up models of testing like self-testing, 
community outreaches, index testing for the hard to reach 
populations. The proportion of patients with suppressed 
viral load is still relatively low partly due to limited 
coverage and implementation of the UNAIDS 90 90 90 
strategy. Without addressing the gaps across the cascade 
in view of populations in hard to reach areas, mortality 
among HIV patients will not drop as expected.
15
 
DISCUSSION 
There is need for managing psychosocial effects and 
stigma associated with HIV among HIV patients to 
address suicidal tendencies and adherence to ART for 
better clinical outcomes. Most facilities in developing 
countries like hospitals, clinics and other recreational 
facilities do not accommodate the disabled population, 
thus limiting them from accessing the most needed HIV 
services towards improving the survival. Some key 
populations or most at risk populations like commercial 
sex workers are criminalized, yet they are more 
vulnerable to HIV than other populations. This could be 
achieved by encouraging social network relationships, 
opening up to trusted family members and peers for 
financial, material and emotional support. Coupled with 
self-care, risk reduction and healthy lifestyle practices 
like regulating number of sexual partners, safe sex 
practices to enhance psychosocial and physical well-
being, patients should be provided with nutritional 
supplements to ensure good adherence to HIV treatment 
thus enhancing viral load suppression.  
The need for specialized management and prioritization 
of HIV care for infants, children and adolescents towards 
improving survival of these populations is overdue. 
Additionally, special attention to non-communicable 
diseases among HIV patients to avoid multidrug 
resistance, unsuppressed viral load, drug adherence and 
risk of death. For instance, to manage cryptococcal 
infections, there is need for improving CrAg screening 
and preventive therapy, a reliable remedy for resource 
limited settings. Building capacity of healthcare workers 
about the incidence, diagnostic procedures, clinical 
symptoms and signs, risk factors and treatment of OIs and 
immune reconstitution inflammatory syndrome amidst 
combination prevention therapy. Prevention, timely 
diagnosis and treatment of OIs like MDRT, PML should 
be prioritized for better clinical outcomes. To sustainably 
achieve these results, integrating NCD care in routine 
HIV management will enhance prevention, awareness 
among HIV patients and the general population.  
Strengthening health care systems across countries to 
ensure improved quality of health care among HIV 
patients with varying needs and conditions is necessary. 
There is need to increase access to HIV testing and 
treatment points nearer to the people to enable timely 
monitoring and management of HIV. This will be made 
possible by increasing coverage of HIV services in hard 
to reach areas and lower health facilities, multipronged 
and differentiated service delivery models like CDDPs, 
CLADS to improve client retention and adherence. Men 
focused and integrated efforts to enhance their access to 
HIV services, for instance assisted partner notification, 
work-based testing, flexi clinic hours friendly for men 
including weekends, integrated HTS campaigns alongside 
HIV screening services for NCDs, VMMC, condoms use, 
will help reverse the epidemic thus improving life 
expectancy. Scale up of community approaches like 
home-based, index testing, self-testing, moonlight clinics 
for key and priority populations. Facilitating campaigns 
against self-prescription of ART, dependence on herbal 
medicines will mitigate new infections among virally 
unsuppressed patients.  
Furthermore, routine monitoring of viral load at 
recommended intervals to ensure right regimens are 
provided to patients appropriately should be 
implemented. Increase in funding towards availing 
implements required in scaling up viral load monitoring 
and HIV management should be enhanced. By and large, 
viral load and other factors stated above need to be 
prioritized by limiting commercialization of HIV by 
donor communities.  
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Whereas most HIV patients recognize biomedical 
measures like VL as a determinant of their health status, 
side effects of ART they encounter are not prioritized as 
critical health complications for HIV patients yet regular 
monitoring of emergencies, drug failure are critical for 
viral suppression. This will require regular case-based 
surveillance throughout the continuum of care for better 
clinical outcomes. 
By and large, with advancements in HIV care and 
treatment, life expectancy has significantly improved 
among HIV patients. This milestone is noted by the 
continued decline in risk of dying for HIV patients. 
Whereas the effect of VL diagnosis on mortality has been 
recognized, the evidence of its effect on lifelong 
treatment is not well documented, one aspect the author 
attempts to contribute to. Therefore, to increase survival 
among HIV patients, a multipronged approach is required 
ranging from timely diagnosis and treatment for HIV, 
reinforcing prevailing recommendations of providing 
vaccination and chemoprophylaxis against key 
preventable infectious diseases among HIV patients. 
These efforts specifically entail managing opportunistic 
infections, stigma, early start of ART, adherence to 
treatment, managing TB and non-communicable diseases 
among HIV patients, addressing psychosocial issues of 
HIV patients and addressing poverty. The instant ART 
enrolment under the test and treat model should be 
boosted by improving quality of counselling, early 
identification of HIV positives, implementing recency 
testing, routine clinical contact of health workers with 
HIV patient, improving electronic and scaling up 
biometric tracking of patients to inform policy and 
efficient allocation of resources. Therefore, efficacy of 
VL suppression on life expectancy of HIV patients is 
influenced by a combination of varying factors, 
interventions and circumstances.  
CONCLUSION  
To assure survival of HIV/AIDS patients on lifelong 
ART, multipronged and innovative approaches are 
required that are focused on person centered monitoring, 
with special attention to individual clinical contact and 
health outcomes as well as effective TB/HIV co-
management. If compounded with quality data that is 
reliable, accurate, transparent of high integrity for 
informed decision making; standardizing health data 
exchange and systems of surveillance; adequate staffing 
of human resources for health and capacity building; 
increased health financing to facilitate availability of 
critical medical supplies and logistics and improved 
laboratory services to facilitate timely laboratory 
proficiency testing quality improvement, recency testing, 
serum CrAg; integrating comprehensive prevention 
packages like VMMC, virtual elimination/Prevention of 
Mother PMTCT including comprehensive reproductive, 
maternal, new born and child health (RMNCH) services; 
other innovative approaches like the PEPFPAR 
adolescent girls and young women (AGYW) initiative, 
CCLAD, CDDP models of care; cervical cancer 
screening among HIV patients; gender based violence 
(GBV) prevention and advocacy mechanisms; addressing 
stigma and targeted interventions for most at risk 
populations like commercial sex workers, (CSWs), 
lesbian, gay, bisexual, transgender, queer or questioning, 
and intersex (LGBTQI) groups; meeting the OVC health, 
education, safety and economic needs. Without the above 
mechanisms, interventions and standards being 
implemented with fidelity and to scale, can the survival of 
HIV patients on ART be attributed to VL suppression 
with systematic availability of HIV testing kits, ARVs 
and commodities; effective linkages of HIV patients; high 
ART coverage; high patient retention and adherence to 
clinical guidelines. 
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